Weekly Digest – December 2025 Weekly Digest – December 2025 22 December 2025: Simcere Zaiming builds exclusive partnership with Ipsen for Simcere Zaiming’s innovative antibody drug conjugate Simcere Zaiming and Ipsen entered an exclusive licensing partnership granting Ipsen global rights outside Greater China to develop, manufacture, and […]
Weekly Digest – December 2025 Weekly Digest – December 2025 22 December 2025: Tongyi Pharmaceuticals announced that it has entered into an exclusive licensing agreement with MultiValent Biotherapies for CBP-1018, a peptide-drug conjugate for the treatment of prostate cancer Tongyi Pharmaceuticals entered an […]
Weekly Digest – December 2025 Weekly Digest – December 2025 15 December 2025: Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer The US […]
Weekly Digest – December 2025 Weekly Digest – December 2025 18 December 2025: AstraZeneca Pharma India gets CDSCO nod for Datopotamab deruxtecan for treating metastatic breast cancer AstraZeneca Pharma India Ltd. announced that the Central Drugs Standard Control Organisation (CDSCO) […]
Weekly Digest – December 2025 Weekly Digest – December 2025 18 December 2025: DATROWAY Type II Variation Application validated in the EU as first-line treatment for patients with metastatic triple negative breast cancer who are not candidates for immunotherapy The […]
Weekly Digest – December 2025 Weekly Digest – December 2025 18 December 2025: JSKN003 was granted Breakthrough Therapy Designation by the FDA for the treatment of PROC Alphamab Oncology announced that the U.S. FDA has granted Breakthrough Therapy Designation to JSKN003 for the treatment of adult patients with […]
Weekly Digest – December 2025 Weekly Digest – December 2025 15 December 2025: Huadong Medicine announced that HDM2012 has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for two indications: gastric cancer or gastroesophageal junction cancer and pancreatic cancer Huadong […]
Weekly Digest – December 2025 Weekly Digest – December 2025 16 December 2025: Cellectar Biosciences announces strategic supply agreement with Ionetix for Actinium-225 and Astatine-211 to advance targeted alpha therapies Cellectar Biosciences announced a multi-year strategic supply agreement with Ionetix Corporation to secure clinical and commercial-scale supplies of the alpha-emitting radioisotopes […]
Weekly Digest – December 2025 Weekly Digest – December 2025 05 December 2025: OBI-902 receives consecutive FDA Orphan Drug Designation indication expanded to gastric cancer including gastroesophageal junction adenocarcinoma OBI Pharma has received a major boost in its oncology pipeline, […]
Weekly Digest – December 2025 Weekly Digest – December 2025 10 December 2025: GSK’227, a B7-H3-targeted antibody-drug conjugate, granted Orphan Drug Designation in small-cell lung cancer by the US FDA GSK’s B7-H3–targeted antibody-drug conjugate, Risvutatug rezetecan (GSK’227), has gained fresh […]
